Last updated: 11/03/2018 10:03:23
Study to assess safety & immunogenicity of GSK Biologicals’ Boostrix (dTpa) vaccine vs. Chinese DT vaccine
Clinicaltrials.gov ID
EudraCT ID
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: Immunogenicity and safety study of GlaxoSmithKline (GSK) Biologicals’ Boostrix (dTpa) vaccine and the Chinese DT vaccine, when administered as booster vaccination in healthy children aged 6-8 years
Trial description: This study will evaluate the safety and immunogenicity of a booster dose of GSK Biologicals’ reduced antigen content diphtheria, tetanus, acellular pertussis (dTpa) vaccine - Boostrix in comparison with Chinese DT vaccine, in children 6-8 years of age.
Primary purpose:
Prevention
Trial design:
Parallel Assignment
Masking:
None (Open Label)
Allocation:
Randomized
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Enrollment:
660
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Zhu F et al. (2010) Booster vaccination against pertussis in Chinese children at six years of age using reduced antigen content diphtheria-tetanus-acellular pertussis vaccine (Boostrix™). Human Vaccines. 6(3):263-269.
Medical condition
Diphtheria, acellular pertussis, Tetanus
Product
SB263855
Collaborators
Not applicable
Study date(s)
March 2007 to May 2007
Type
Interventional
Phase
3
Participation criteria
Sex
Female & Male
Age
6 - 8 years
Accepts healthy volunteers
Yes
- A male or female between, and including, 6-8 years of age at the time of vaccination,
- Written informed consent obtained from the parent or guardian of the subject,
- Subjects who have received a total of 4 doses of DTP vaccine in the first 2 years of life, subjects who have received previous DTP booster vaccination since administration of the fourth dose of vaccine in second year of life can not participate.
- Subjects with history of diphtheria, pertussis or tetanus diseases can not participate.
Inclusion and exclusion criteria
Inclusion criteria:
- A male or female between, and including, 6-8 years of age at the time of vaccination,
- Written informed consent obtained from the parent or guardian of the subject,
Exclusion criteria:
- Subjects who have received a total of 4 doses of DTP vaccine in the first 2 years of life, subjects who have received previous DTP booster vaccination since administration of the fourth dose of vaccine in second year of life can not participate.
- Subjects with history of diphtheria, pertussis or tetanus diseases can not participate.
Trial location(s)
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2007-12-05
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click hereAccess to clinical trial data by researchers
Visit website